News | August 10, 2024
IOL Chemicals and Pharmaceuticals posts Q1 FY25 PAT at Rs. 29.7 Cr
The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24
The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
Nearly 200 participants from 50 Unani Academia and Council participated
The pharma market is showing encouraging signs of improvement, positioning us well for future growth
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
Both departments will be equipped with specialized professionals and state-of-the-art facilities ensuring the highest standards of care
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
Dr. Vinod Kumar Paul highlighted the huge gap between the demand for and supply of organs
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
Q1 FY25 revenues up 20% YoY to Rs. 1,002 crore
Subscribe To Our Newsletter & Stay Updated
